Generate Biomedicines, Inc. Common Stock (GENB) — Cash Flow-to-Debt Ratio
Generate Biomedicines, Inc. Common Stock (GENB) has a Cash Flow-to-Debt Ratio of -0.72x as of March 2026, meaning its operating cash flow of $-80.39 Million could theoretically repay -1% of its total liabilities ($110.94 Million) in one year. Explore Generate Biomedicines, Inc. Common Stock cash flow conversion to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Generate Biomedicines, Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Generate Biomedicines, Inc. Common Stock across 2 annual periods. Also explore Generate Biomedicines, Inc. Common Stock balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Generate Biomedicines, Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Generate Biomedicines, Inc. Common Stock. For market capitalisation and broader financial context, see GENB company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | $-200.62 Million | $953.38 Million | ▼ -70.4% |
| 2024 | -0.12x | $-117.75 Million | $953.35 Million | — |